Translate Bio

LEXINGTON, MA · Founded 2016 · CIK 0001693415 · Biotech · Acquired

mRNA therapeutics platform for pulmonary and systemic diseases

translate.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$98M
2 Form D · May 2019
89 months since last filing
Contracts
—
No federal contracts on record
Patents
40
27 granted · 13 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$50,999,987
Private capital raisedForm D · SEC$47,454,990
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2392CH3 BIOSYSTEMS, LLC——
2393Autifony Therapeutics——
2394EXARCA PHARMACEUTICALS, LLC——
2395Translate Bio—$98M
2396NeuvaRx, LLC——
2397Antiva Biosciences—$81M
2398Fate Therapeutics—$236M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 17 related persons
  • Ann BarbierExecutive Officer
  • Daniella BeckmanDirector
  • Paul BurgessExecutive Officer
  • Paula CloghessyExecutive Officer
  • Brian FentonExecutive Officer
  • Jean-Francois FormelaDirector
  • Jean- Francois FormelaDirector
  • Brian GallagherDirector
  • Michael HeartleinExecutive Officer
  • Owen HughesDirector
  • Daniel LynchDirector
  • Thomas McCauleyExecutive Officer
  • Robert MeyerDirector
  • Robert PlengeDirector
  • Ronald Renaud, Jr.Director · Executive Officer
  • John SchroerExecutive Officer
  • Richard WoosterExecutive Officer

Patents

USPTO · 27 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.